Fujian Genohope Biotech Ltd: GLP-1 import refusal records
Has FDA refused imports of GLP-1 products from Fujian Genohope Biotech Ltd?
Yes. FDA’s import refusal records list 9 refused shipment lines declared as made by Fujian Genohope Biotech Ltd (China) whose FDA product code names tirzepatide and semaglutide, from Oct 28, 2024 to May 28, 2025. 7 of them carry a product code that FDA’s Import Alert 66-80 lists as a GLP-1 API or powder form.
- Country
- China
- City in FDA records
- Futian
- FEI numbers on the lines
- 3025263427
- Refused lines
- 9
- Lines with an Import Alert 66-80 API or powder code
- 7
- Drugs named in the product codes
- Tirzepatide, Semaglutide
- Refusal dates
- Oct 28, 2024 to May 28, 2025
The declared manufacturer is the firm named on the import entry. A refusal is FDA’s decision on one shipment line; it is not a finding about the firm’s other products.
Import Alert 66-80’s Green List (published Oct 9, 2026) prints a redaction in place of every firm name, so this index cannot say whether Fujian Genohope Biotech Ltd is on it.
Refused shipment lines
| FDA refusal charges | Shipment ID | ||||
|---|---|---|---|---|---|
| May 28, 2025 | China | 61PCT74 TIRZEPATIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. | BYA-2502829-1/12/1A |
| May 28, 2025 | China | 61PCT74 TIRZEPATIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. | BYA-2502829-1/12/1B |
| Feb 28, 2025 | China | 61PCT74 TIRZEPATIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | BYA-2500742-8/11/1 |
| Feb 28, 2025 | China | 61PCT74 TIRZEPATIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | BYA-2500742-8/11/2 |
| Feb 28, 2025 | China | 61PCT74 TIRZEPATIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | BYA-2500742-8/11/3 |
| Nov 4, 2024 | China | 61PBY72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). | AEK-5721091-4/11/1 |
| Nov 4, 2024 | China | 61PBY74 TIRZEPATIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). | AEK-5721091-4/21/1 |
| Oct 28, 2024 | China | 61PCS72 SEMAGLUTIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Further Manuf | NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | AEK-5719160-1/11/1 |
| Oct 28, 2024 | China | 61PCS74 TIRZEPATIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Further Manuf | NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). | AEK-5719160-1/21/1 |
FDA refusal charges on these lines
A line can carry several charges. Text is FDA’s charge statement, verbatim.
| NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k). | 4 |
| FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act. | 4 |
| DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. | 2 |
| UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA). | 2 |
FDA NDC listings
FDA’s NDC Directory files, read Nov 15, 2026, list 5 products naming liraglutide, semaglutide and tirzepatide under the labeler name “Fujian Genohope Biotech Ltd.”, matched to this import records page by exact name. Marketing categories as FDA gives them: BULK INGREDIENT (5).
| 84502-104 | Not given | Liraglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Oct 17, 2024 | None given | Dec 31, 2027 | Unfinished drugs |
| 84502-101 | Not given | semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jul 2, 2024 | None given | Dec 31, 2027 | Unfinished drugs |
| 84502-109 | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Oct 17, 2025 | None given | Dec 31, 2027 | Unfinished drugs |
| 84502-113 | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | May 19, 2026 | None given | Dec 31, 2027 | Unfinished drugs |
| 84502-103 | Not given | Tirzepatide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Jul 31, 2024 | None given | Dec 31, 2027 | Unfinished drugs |
FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA Import Alert 66-80
- FDA Import Refusal Report bulk files
- FDA Data Dashboard: import refusals
- FDA National Drug Code Directory (download files)
- FDA: NDC product file definitions
- openFDA drug NDC endpoint (count cross-check)
Records last pulled Nov 15, 2026. Every entry links to the original public record.
9 lines from FDA files read Nov 15, 2026.